FDA approves hematologic malignancy therapy

The U.S. Food and Drug Administration has approved the use of ziftomenib (Komzifti; Kura Oncology-Kyowa Kirin) in patients with relapsed or refractory NPM1-mutated acute myeloid leukemia.

The FDA noted that the drug comes with boxed warnings for differentiation syndrome and a low risk of QTc interval prolongation, as well as the potential for the drug to cause fetal harm. A similar drug known as revumenib (Revuforj; Syndax Pharmaceuticals), previously approved by the FDA, also includes a boxed warning for QTc interval prolongation.

Read more: Reuters

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.